For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Mitotix, Inc.

Calculating rank

USPTO Granted Patents = 16

Forward Citations = 239

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Giulio Draetta (11 out of 12 patents)

Mark Rolfe (6 out of 8 patents)

Guillaume Cottarel (6 out of 10 patents)

4. Veronique Damagnez (5 out of 14 patents)

5. Jeno Gyuris (4 out of 10 patents)

6. Vivian Berlin (3 out of 13 patents)

7. Lou Lamphere (3 out of 4 patents)

8. Peggy L Beer-Romero (2 out of 3 patents)

9. Maria Isabel Chiu (2 out of 6 patents)

10. Jens W Eckstein (2 out of 2 patents)

11. Kollol Pal (1 out of 10 patents)

12. Serene Josiah (1 out of 6 patents)

13. Yoshikazu Ohya (1 out of 3 patents)

14. David H Beach (1 out of 34 patents)

15. David E Levin (1 out of 2 patents)

16 patents: Sort by Forward Citations

1. 6251585 - Assay and reagents for identifying anti-proliferative agents (2001-06-26),

2. 6146842 - High-throughput screening assays utilizing metal-chelate capture (2000-11-14),

3. 6117641 - Assays and reagents for identifying anti-fungal agents and uses related (2000-09-12),

4. 6068982 - Ubiquitin conjugating enzymes (2000-05-30),

5. 6060262 - Regulation of I Kappa B (I.kappa.B) degradation and methods and reagents (2000-05-09),

6. 6015692 - CDC37 cell-cycle regulatory protein and uses related thereto (2000-01-18),

7. 5981699 - Human ubiquitin conjugating enzyme (1999-11-09),

8. 5968761 - Ubiquitin conjugating enzymes (1999-10-19),

9. 5858987 - E6AP antisense constructs and methods of use (1999-01-12),

10. 5801015 - Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 (1998-09-01),

11. 5756671 - CDC37 cell-cycle regulatory protein, and uses related thereto (1998-05-26),

12. 5744343 - Ubiquitin conjugating enzymes (1998-04-28),

13. 5733920 - Inhibitors of cyclin dependent kinases (1998-03-31),

14. 5691147 - CDK4 binding assay (1997-11-25),

15. 5672508 - Inhibitors of cell-cycle progression, and uses related thereto (1997-09-30),

Company Overview

Mitotix, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative therapeutics targeting mitochondrial dysfunction. The organization focuses on advancing treatments for a range of diseases linked to mitochondrial health, leveraging cutting-edge research in cellular biology and biochemistry. Mitotix aims to address unmet medical needs through its proprietary technologies, contributing to the evolving landscape of precision medicine and enhancing patient outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

16 Patents

#164 in Cambridge, MA

#1,204 in Massachusetts

#19,966 in US

#37,952 in the World

Cambridge, MA, United States of America

Mitotix, Inc.

Forward Citations = 239

20 inventors:

Giulio Draetta (11 out of 12 patents)

Mark Rolfe (6 out of 8 patents)

Guillaume Cottarel (6 out of 10 patents)

4. Veronique Damagnez (5 out of 14 patents)

5. Jeno Gyuris (4 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mitotix, Inc.. Retrieved from https://idiyas.com/company/mitotix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…